MARVEL BIOSCIENCES CORP - MBCOF STOCK NEWS

Marvel Biosciences has been awarded a $300,000 Alberta Innovates AICE Validates grant to support the preclinical validation of MB204 for Alzheimer's disease treatment. The company's drug candidate, MB204, is an adenosine A2A receptor antagonist designed to target the underlying pathology of Alzheimer's, rather than just managing symptoms. The company has completed cGMP synthesis and 4-week GLP toxicology studies, and will conduct a chronic long-term preclinical study to validate MB204's effectiveness before moving to Phase 1 clinical trials.

Marvel Biosciences (TSXV: MRVL, OTCQB: MBCOF) reported promising interim results from a preclinical study of MB204 as a potential treatment for Rett syndrome. Conducted by experts at the iBraiN Institute in France, the study showed that chronic oral dosing of MB204 restored social interaction behaviors to near-normal levels in a preclinical model of Rett syndrome. These improvements in cognitive function may represent a pivotal shift in therapy.

Led by Dr. Julie Le Merrer and Dr. Jerome Becker, the study found that 14 days of MB204 treatment (10 mg/kg oral dosing once daily) nearly reversed social and behavioral deficits. MB204 outperformed the approved drug Trofinetide (100 mg/kg via intraperitoneal injection once daily) on most studied endpoints and exhibited a distinct carry-over effect lasting at least 14 days after dosing cessation.

Marvel CSO Dr. Mark Williams noted that MB204 showed profound effects on restoring social behaviors, suggesting potential synaptic plasticity induction. Marvel CEO Rod Matheson emphasized the compelling nature of the data, hinting at improved therapies for Rett syndrome.

Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) has reported positive results from a study on MB204 in the Oprm1 mouse model of autism. The research, conducted by Drs. Julie Le Merrer and Jerome Becker, showed that a single oral dose of MB204 successfully reversed social behavior deficits typically seen in the model within one hour of administration.

Key findings include:

• A high dose (2.5 mg/kg) of MB204 significantly restored social behavior in all measured endpoints (p<0.0001)
• A lower dose (1 mg/kg) also reversed nearly all social behavior deficits
• The higher dose even outperformed normal (non-autistic) mice on several endpoints

The researchers noted that MB204 showed more improvement and a hyper-social effect compared to previously tested drugs. Marvel is now testing MB204 in other autism spectrum disorder models, including Rett syndrome (Mecp2) and Fragile X syndrome (Fmr1).

Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) has announced a collaboration with the FRAXA Research Foundation to test its lead asset MB204 in a preclinical model of Fragile X syndrome (FXS). FXS is a common cause of inherited intellectual disability, affecting approximately 1 in 4000 males and 1 in 8000 females. The collaboration aims to explore MB204's potential as a treatment for FXS and other forms of autism spectrum disorder.

MB204 is an adenosine A2a receptor antagonist and a novel fluorinated derivative of the approved anti-Parkinson's drug Istradefylline. FRAXA will test MB204 through its internal screening program this year. The foundation previously identified BPN14770, which is currently in Phase 3 trials for Fragile X. Notably, there is currently no approved drug to treat FXS.

Marvel Biosciences Corp. (TSXV: MRVL) has announced the grant of 1,475,000 incentive stock options to certain directors and officers. The options, approved on July 23, 2024, have an exercise price of $0.125 per share, matching the closing price on July 22, 2024. These options are exercisable until July 23, 2029, and will vest in three tranches: 1/3 immediately, 1/3 on the first anniversary, and 1/3 on the second anniversary of the grant. The stock options are subject to the company's stock option plan and TSX Venture Exchange requirements.

Marvel Biosciences (TSXV: MRVL; OTCQB: MBCOF) has extended its collaboration with the iBraiN Institute to test its lead drug MB204 in a pre-clinical model of Rett syndrome, a rare genetic neurological disorder. This follows promising results from earlier tests on an autism model. The study will conduct a head-to-head comparison of MB204 against Trofinetide, the only approved treatment for Rett syndrome. Dr. Julie Le Merrer and Dr. Jerome Becker, lead investigators at the iBraiN Institute, believe modulating the adenosine A2a receptor could improve outcomes. Marvel's CEO Rod Matheson expressed optimism that the ongoing research will lead to significant insights and potential treatments for Rett syndrome.

Marvel Biosciences Corp. (TSXV: MRVL) has closed its non-brokered private placement, raising $500,000 through the issuance of 5,000,000 units at $0.10 per unit. Each unit comprises one common share and one warrant, exercisable at $0.15 per share until July 19, 2026. The company paid $25,200 in finders fees and issued 252,000 finder's warrants. Proceeds will fund pre-clinic experiments on MB-204 in chronic Alzheimer's disease and Autism models, and general working capital. The offering is subject to TSX Venture Exchange approval, with securities having a four-month hold period.

Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) highlighted a new research paper published by Dr. David Blum, a member of their scientific advisory board. The study, published in 'Brain', discovered that early increases in adenosine A2A receptor (A2aR) in neurons can result in memory loss in Alzheimer's mouse models, specifically linked to Tau phosphorylation at the AT8 site rather than amyloid plaques. Marvel's lead asset, MB204, an A2aR antagonist, has shown promise in reducing Tau phosphorylation in initial studies. This suggests that MB204 could be a valuable approach in treating Alzheimer's.

Marvel Biosciences, through its subsidiary Marvel Biotechnology, focuses on developing new synthetic derivatives of off-patent drugs to target diseases like Alzheimer's, depression, anxiety, ADHD, cancer, and non-alcoholic steatohepatitis. By repurposing existing drugs, Marvel aims to reduce development time, cost, and risk.

On June 21, 2024, Marvel Biosciences (TSXV: MRVL) announced an update regarding its private placement unit offering. The TSX Venture Exchange (TSXV) has conditionally accepted Marvel's proposed non-brokered private placement, initially announced on May 16, 2024. Additionally, the company has been granted a two-week extension until July 17, 2024, to finalize its documentation related to the offering. This extension provides Marvel more time to complete necessary formalities for the private placement, which aims to raise funds for its ongoing business operations and research initiatives.